Controversial Treatment for Autism May Do More Harm Than Good, Baylor University Researchers FindNov. 29, 2012
Follow us on Twitter:@BaylorUMediaCom
Contact: Tonya B. Lewis, (254) 710-4656
WACO, Texas (Nov. 29, 2012) --A controversial treatment for autism spectrum disorder (ASD) is not only ineffective but may be harmful, according to a study conducted by Baylor University researchers.
The treatment, known as chelation, attempts to eliminate metals such as mercury from the body.
"The chemical substances used in chelation treatment have a myriad of potentially serious side effects such as fever, vomiting, hypertension, hypotension, cardiac arrhythmias and hypocalcemia, which can cause cardiac arrest," said Tonya N. Davis, Ph.D., assistant professor of educational psychology in Baylor's School of Education and co-author of the study. To view the study, published in Research in Autism Spectrum Disorders, visit http://www.sciencedirect.com/science/article/pii/S1750946712000724.
In one example mentioned in the research, "a 5-year-old with ASD died from cardiac arrest caused by hypocalcemia while receiving intravenous chelation." And, a 2008 clinical study of chelation treatment for autism was suspended due to potential safety risks associated with chelation.
"Chelation therapy represents the 'cart before the horse' scenario where the hypothesis supporting the use of chelation was not validated prior to using it as a form of treatment. Evidence does not support the hypothesis that ASD symptoms are associated with specific levels of metals in the body," said Davis, supervisor of the Applied Behavior Analysis Program at the Baylor Autism Resource Center.
VIDEO: Tonya N. Davis, Ph.D., gives tips on how to decipher research on autism treatments.
In the study, Davis and colleagues reviewed the research findings of five published studies on chelation. In the studies, 82 participants ages 3 to 14 received chelation treatment ranging from one to seven months.
Of the five studies, four showed mixed results--some positive and negative outcomes for each of the study participants--and one study showed all positive results. But after closer review, Davis and her research team found "methodological weaknesses" in the studies.
"Several studies used numerous treatments at once in addition to chelation that made it impossible to determine if the positive results could be attributed to chelation alone," Davis said.
Ultimately, Davis found that the research studies did not support the use of chelation as some have claimed and were "insufficient, which is the lowest level of certainty."
"The use of chelation to remove metals from the body in order to ameliorate ASD could be seen as unfounded and illogical," said Davis.
Despite the risks and lack of evidence supporting chelation, in an Internet survey, more than 7 percent of parents said they have tried chelation treatment for their children.
"Other researchers have found that validation of a treatment, or lack thereof, does not appear to have an influence over what treatment parents elect to use. Most parents believe in 'leaving no stone unturned' when trying to treat their children with ASD and are willing to try anything they believe might help their child," Davis said.
Davis and her colleagues hope their findings can help parents make decisions about the course of treatment to undertake for their children.
"My hope is that this research will help parents make informed choices when selecting treatments for their child with ASD. While I understand a parent's desire to try anything and everything that may help their child, as a researcher, it is difficult to watch a family spend time, money, and resources on interventions that research has found to be ineffective, or worse, potentially dangerous," Davis said.
Other contributing authors to the study include: Daelynn Copeland and Shanna Attai of Baylor; Mark O'Reilly and Soyeon Kang of The University of Texas at Austin; Russell Lang of Texas State University-San Marcos; Mandy Rispoli of Texas A&M University, Jeff Sigafoos of Victoria University of Wellington, New Zealand; Giulio Lancioni of the University of Bari, Italy, and Austin Mulloy of Virginia Commonwealth University.
ABOUT BAYLOR UNIVERSITY
Baylor University is a private Christian University and a nationally ranked research institution, characterized as having "high research activity" by the Carnegie Foundation for the Advancement of Teaching. The University provides a vibrant campus community for approximately 15,000 students by blending interdisciplinary research with an international reputation for educational excellence and a faculty commitment to teaching and scholarship. Chartered in 1845 by the Republic of Texas through the efforts of Baptist pioneers, Baylor is the oldest continually operating University in Texas. Located in Waco, Baylor welcomes students from all 50 states and more than 80 countries to study a broad range of degrees among its 11 nationally recognized academic divisions. Baylor sponsors 19 varsity athletic teams and is a founding member of the Big 12 Conference.
ABOUT BAYLOR SCHOOL OF EDUCATION
The Baylor School of Education is accredited by the National Council for Accreditation of Teacher Education and consists of four departments: Curriculum and Instruction (preparation for classroom teachers and specialists); Educational Administration (post-graduate preparation for school leadership); Educational Psychology (undergraduate and graduate programs for those who are interested in learning, development, measurement, and exceptionalities); and Health, Human Performance and Recreation (preparing for sport- and health-related careers, athletic training and careers in recreational professions, including churches).The School of Education enrolls more than 1,000 undergraduate students and 300 graduate students, employs 70 faculty, and is one of the few school s in the State of Texas that offers a yearlong teaching internship.